Histone deacetylase inhibitors: a potential epigenetic treatment for Duchenne muscular dystrophy
Epigenomics Review of the rationale behind the use of an epigenetic therapy as a potential pharmacological treatment of Duchenne muscular dystrophy, by Silvia Consalvi, Valentina Saccone and Chiara Mozzetta, from IRCCS Santa Lucia Foundation and CNR Institute of Cellular Biology & Neurobiology (both Rome, Italy).
Please sign in or register for FREE
Sign in to RegMedNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Regenerative Medicine FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RegMedNet account also gives you access to communities on drug discovery, real-world evidence and 3D printing in medicine. Find out more>>